Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. (30th May 2020)

• Record Type: Journal Article
• Authors: Scirocco, Chiara; Gubbiotti, Andreina; Sebastiani, Alfredo; Sebastiani, Gian Domenico
• Other Names: Koarada Syuichi Academic Editor.
• Is Part Of: Case reports in rheumatology. Volume 2020(2020)
• Publication Date: 2020-05-30
• Subjects: Rheumatology -- Periodicals; Rheumatology -- Case studies -- Periodicals; Rheumatic Diseases; Connective Tissue Diseases; Rheumatology; Periodicals; Electronic journals; Case studies; Periodicals; 616.723
• DOI: 10.1155/2020/8145790
• Languages: English
• ISSNs: 2090-6889

Abstract

Abstract : In this paper, we report a challenging case of a middle-age woman who developed antimelanoma differentiation-associated protein-5 dermatomyositis (anti-MDA5 DM) with interstitial lung disease (ILD) and was successfully treated with rituximab (RTX), after failure of a first-line therapy.